|
|
|||
|
Mountain View, CA - June 18, 2007 – Matisse Software today announces that Pfizer Global Research and Development selected Matisse 8 to manage high-quality digital media of pre-clinical studies. The PGRD lab in Amboise, which provides toxicology and exploratory study support for the company, performs ophthalmological research to determine the pre-clinical safety of compounds. Pfizer researchers in Amboise need a simple, accurate and secure means to document the finest eye pathology as well as to manage large volumes of ophthalmic images. “Our unique approach to ophthalmological research requires a complete imaging solution for the capture and management of high quality ophthalmic images,” said Dr Yann Tessier, Director Comparative Medicine at Pfizer, “and Matisse Software has been an ideal partner to deliver us with a cost-effective leading-edge solution that meets our requirements.” Matisse Software in close collaboration with Pfizer scientists has developed Keops, a Matisse-based solution to collect, analyze, process and store high-quality digital media of pre-clinical or clinical studies. Uniquely designed to run in a highly regulated industrial environment, Keops provides a unique fast acquisition process using direct connection to a wide range of high quality imaging instruments. “Matisse innovative database technology combined with our unique expertise for building mission critical applications in a regulated environment was key to deliver Pfizer with a secure, efficient and easy to use solution.”, said Didier Cabannes, CEO of Matisse Software. Some of the specific benefits of Keops include:
About Matisse Software ### Matisse and the Matisse logo are the trademarks of Matisse Software Inc. All Rights Reserved. All other trademarks are the property of their respective holders.Matisse Software, Inc. Press Contact |
About Matisse | Products | Services | Customers | Partners | Developers |
|
Home | Contact | Terms of Use | Terms and Conditions | Privacy Policy © 2020 Matisse Software Inc. |